You searched for "VEGF"
In conversation with Professor Usha Chakravarthy (2018)
Professor Chakravarthy popped by the Eye News stand at the 2018 Royal College of Ophthalmologists Annual Congress after her excellent Bowman Lecture. She gave us a summary of her presentation, which looked at how our understanding of AMD has changed...Management of diabetic macular oedema (DMO)
1 February 2018
| Kurt Spiteri Cornish
|
Retina / Uvea / Vitreous
|
Anti-VEGF therapy, Diabetic macular edema, Steroids
The authors present guidelines on current diagnostic and therapeutic procedures in the management of DMO. Fluorescein angiography (FA) and optical coherence tomography (OCT) are recommended before starting treatment to help diagnose and stage DMO, and can be repeated if there...
Injection frequency and anatomic outcomes following conversion to Aflibercept in neovascular AMD patients
1 December 2014
| Jonathan Chan
|
Retina / Uvea / Vitreous
|
Degeneration, Macula, Treatment Medical
This is a retrospective study of patients with neovascular age-related macular degeneration (AMD) treated with intravitreal Lucentis and / or Avastin who were switched to aflibercept (Eylea). This study was carried out by the Casey Eye Institute retinal clinics, between...
Management of DMO and PDR in 2019
An evidence-based approach to the management of diabetic macular oedema (DMO) and proliferative diabetic retinopathy (PDR) in 2019 was outlined by Sobha Sivaprasad, UK, in presentations during the Diabetic Retina scientific session September 6 2019, at the 19th European Society...The role of inflammation in the pathophysiology of DMO
1 February 2016
| Fiona Harris, Spyridon Chalkiadakis, Simon Taylor (Prof)
|
Retina / Uvea / Vitreous
Diabetic macular oedema (DMO) is a major cause of visual loss in diabetes, with a complex multifactorial pathogenesis. In the UK alone it is estimated that there are nearly 2.5 million diabetic patients aged over 12 years. Approximately 65,000 of...
Ranibizumab safety in pregnancy
1 December 2018
| Sofia Rokerya
|
Retina / Uvea / Vitreous
Vascular endothelial growth factor (VEGF) plays a pivotal role during pregnancy, and systemic anti-VEGF administration during this period should thus be avoided. VEGF is expressed in multiple embryonic and foetal tissues during development, with the highest levels found in the...
Discussing treatment modalities for bilateral wet AMD
1 December 2014
| Marie Tsaloumas, Bushra Mushtaq
|
Retina / Uvea / Vitreous
A 65-year-old lady with bilateral wet AMD and vision of 6/24 comes with an internet search about current therapies. How do you explain the various treatment modalities available? There are two NICE approved treatments for wet age-related macular degeneration (AMD)....
Treatment efficacy of stage 4 ROP
4 February 2021
| Fiona Rowe (Prof)
|
Paediatric Ophthalmology / Strabismus
This study aimed to determine the efficacy of combined vitrectomy and anti-VEGF injection for advanced stage 4 ROP with extensive neovascular proliferation (NF). The study included nine infants; six bilateral and three unilateral. Seven were female and the mean gestational...
Outcomes of reinjection of Ranibizumab for reactivation of retinopathy of prematurity
5 June 2023
| Ivan Yip
|
Paediatric Ophthalmology / Strabismus
The authors present their data from Egypt assessing the effects of Ranibizumab reinjection for neonates with retinopathy of prematurity (ROP). Doses given were 0.25mg/0.025mL. They screened 2318 infants with 115 (5%) of infants with a mean post menstrual age (PMA)...
MicroRNA inhibits corneal neovascularisation
1 August 2018
| Graham Wallace
|
Cornea / External Eye Disease
|
Biomechanical stress, Corneal epithelium, MicroRNA-204, Neovascularization, VEGF, VEGFR2
MicroRNAs (miR) are small non-coding RNA that target mRNA for destruction. MiR target about 30% of the protein coding genes and fine tune their expression. MiR have been shown to be involved in several cellular processes including cell cycle, tissue...
Akimba mice, a model of human diabetic retinopathy
1 October 2014
| Graham Wallace
|
Retina / Uvea / Vitreous
|
Akimba, BRB, PLVAP, blood-retinal barrier, diabetic macular edema, diabetic retinopathy, mouse models, retina
Diabetic retinopathy (DR) is a major complication of diabetes and a growing problem as the systemic disease becomes more prevalent. DR develops insidiously from an asymptomatic form through to vascular damage that leads to oedema and breakdown of the blood-retinal...
Considerations in the management of retinal disorders
1 October 2017
| Rod McNeil
|
Retina / Uvea / Vitreous
Vision research presentations and publications explore practice considerations in the management of AMD and diabetic retinopathy. Over the past two decades in Europe there has been a decreasing prevalence of age-related macular degeneration (AMD) and an improvement in visual acuity...